We've been keeping Eyes On the updates coming out along with the 2Q25 Results. Lots of news on strategic Plans, M&A, Clinical Data, and more. 

 This month we've had Eyes On The BBB and potential timing and impact on the BioPharma sector. This is a dynamic area, with many different news bytes daily, let us know what you'v e seen and what sources you are following.

We've had Eyes on several firms that are actively executing on their strategic plans to ensure competitiveness in their markets. Take a look at how BioNTech, Novo Nordisk, and Merck are adapting to changing markets and technologies.

This week we've kept Eyes On the MFN and Tariff news, plus the Moderna x HHS Break-up and the Lilly x SiteOne Deal. The BioPharma Marketplace is in flux and we're watching to see how everyone is adapting and re-aligning their strategies.

We're catching up on the latest news and views surrounding the BioPharma Industry & Tariffs.

Just two weeks after our initial blogpost was published, 23andMe has made headlines again — this time for being acquired by Regeneron Pharmaceuticals in a deal valued at $256 million.

We've been keeping Eyes On Regulatory news, both in the US and Europe. We're sharing a few of the updates from the past few weeks on approval timing, staffing changes, clinical results, international company coalitions, and more.

Spark Therapeutics, the gene therapy division that Roche purchased for $4.3 billion in 2019, has undergone a significant reorganisation.

Lenacapavir from Gilead Sciences has shown promise when dosed even more widely apart - only once a year...

JnJ, Legend expanding cell therapy capacity.

This month we've been watching how different companies are managing their pipelines, and keeping Eyes On other hot news topics.

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

This week, we had eyes on data readouts, launch metrics, M&A, and more. Catch up with the news from Roche, AstraZeneca, Lundbeck, and AbbVie

We've had Eyes On some of the recent deals, results, and investor actions. Check out the happenings at Sanofi/Opella, Pfizer, Regeneron, and

Last month, we had Eyes On some of the latest approvals, M&A and litigation. Read more about AbbVie, Genentech, Lundbeck, and GSK ...

Eye's on the Amgen data releases for gMG & Atopic Dermatitis, the BMS approval of Cobenfy for schizophrenia, and Pfizer's Oxbryta recall...

This month, we've had Eyes on investment trends, strategic restructuring, and FDA decisions. Fall seems to be gearing up, and we can't wait

We've had our Eyes On some of the latest Pharmaceutical news including approvals, partnering, mergers, research programs, and

News & Views - sharing some oncology, AZD, M&A tidbits that caught our eye.

his week we've been looking at the competition heating up due to a combination of M&A, biosimilar entrants, and new clinical data ...